Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

COCP vs ENTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–1 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: COCP 2 – 3 ENTX (1 Tie) Matrix Metrics: COCP 1 – 6 ENTX

As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). COCP carries a Unified Composite Score of 38.7/100 (SELL) at $1.01 (N/M Forward P/E, -3063.6% operating margin), whereas ENTX carries 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. COCP 38.7/100 SELL) and 1.07β · 45% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCP vs ENTX
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.82% 1D
Market Cap $18.9M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 0.97β · 55% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.6 · SMA20: $1.00 · SMA50: $1.07
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap $541.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 45% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 35.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.8 · SMA20: $3.09 · SMA50: $2.90

6-Pillar Scorecard Institutional Category Breakdown (COCP 2 – 3 ENTX)

Columns: Metric · COCP · ENTX
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 47.3x N/M
2. Growth & Scale COCP
Revenue Growth (YoY) +26.9% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $330,000 N/A
Market Cap $18.9M $541.6M
3. Profitability & Quality ENTX
Gross Margin N/A N/A
Operating Margin -3063.6% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -311.7% -20.3%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$7.6M -$16M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.3M Net Cash $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 113.8% (32nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCP (1) vs ENTX (6)
Institutional Metric COCP ENTX Criterion Row Edge
Market Capitalization
Scale
$18.9M $541.6M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+26.9% -100.0% Higher Growth COCP
Operating Margin (TTM)
Profitability
-3063.6% 0.0% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-311.7% -20.3% Higher ROE ENTX
52-Week Range Position
Momentum
20% ($1–$2) 64% ($1–$4) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
0.97β · 55% Vol 1.07β · 45% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
38.7 / 100 (SELL) 53.5 / 100 (HOLD) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
$330,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 47.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($3.3M Net Cash) -$16M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +4.85 pp
COCP: +7.23% · ENTX: +2.38%
3M Horizon ENTX +8.13 pp
COCP: -11.35% · ENTX: -3.22%
6M Horizon ENTX +148.75 pp
COCP: -11.74% · ENTX: +137.01%
1Y Horizon ENTX +12.53 pp
COCP: -1.46% · ENTX: +11.07%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCP Revenue ENTX Revenue COCP Op. Margin ENTX Op. Margin Margin Leader
FY2011 $10M N/A -30.6% N/A COCP
FY2019 $10M N/A -737.4% N/A COCP
FY2020 $0M $0M -476.0% -3059.7% COCP
FY2021 N/A $0M N/A -2139.6% ENTX
FY2022 N/A $0M N/A -9714.2% ENTX
FY2024 N/A $0M N/A -5295.6% ENTX
FY2025 N/A $0M N/A -27450.0% ENTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
80d in phase · OBV NEUTRAL
Current IV 113.8%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $18.9M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ COCP vs ENTX Key Questions & Quantitative Answers

As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). COCP carries a Unified Composite Score of 38.7/100 (SELL) at $1.01 (N/M Forward P/E, -3063.6% operating margin), whereas ENTX carries 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ENTX earns the overall head-to-head edge with a stronger Unified Composite Score (53.5/100 HOLD vs. COCP 38.7/100 SELL) and 1.07β · 45% Vol risk profile, whereas COCP leads top-line expansion (+26.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

COCP leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2011 to FY2025), COCP cumulative revenue shifted +0.0% while ENTX shifted N/A. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.

COCP screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 47.3x EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus ENTX (-20.3% ROE) capital efficiency.

In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 55% Vol realized risk). By comparison, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.